Spago Nanomedical AB (SPAGO) AI Stock Analysis

• Market Cap: €74.10M
• Dividend Yield: N/A
• Average Volume (3M): 1.01M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.21
• Revenue Growth: -48.15%
• EPS Growth: 51.95%
• Country: SE
• Employees: 13
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.01
• Shares Outstanding: 661,572,800
• 10 Day Avg. Volume: 1,158,815
• 30 Day Avg. Volume: 1,005,829
• PEG Ratio: 0.04
• Price to Book (P/B): 1.74
• Price to Sales (P/S): 30.30
• P/FCF Ratio: -1.66
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): -0.6
• Revenue Forecast (FY): €18.95M

• Rating: 38 Underperform
• Price Target: ―

Spago Nanomedical AB's overall stock score is driven by significant financial challenges, including persistent losses and negative equity. Despite some upward technical momentum, the stock's negative valuation metrics and lack of profitability weigh heavily on its score. Investors should be cautious due to these financial risks.

Spago Nanomedical AB Business Overview & Revenue Model

Company Description

Spago Nanomedical AB (publ) develops nanomedicines for cancer diagnostics and treatment primarily in Sweden. It is involved in the development of SN132D, a gadolinium-free MRI contrast agent for the treatment of breast and pancreas cancer under the SpagoPix project; and SN201, a radionuclide therapy for treatment of advanced and metastatic cancer under the Tumorad project. The company was formerly known as Spago Imaging AB (publ) and changed its name to Spago Nanomedical AB (publ) in May 2014. Spago Nanomedical AB (publ) was incorporated in 1999 and is based in Lund, Sweden.

How the Company Makes Money

Spago Nanomedical AB generates revenue through the development and commercialization of its nanomedical products, particularly in the oncology space. The company's primary revenue streams include licensing agreements, research and development partnerships, and potential future sales of its nanomedical solutions. Additionally, Spago Nanomedical collaborates with pharmaceutical companies and research institutions, which can provide funding and support for its projects. Revenue is also derived from grants and governmental or institutional funding aimed at advancing innovative cancer treatments and diagnostic tools.

Spago Nanomedical AB Financial Statement Overview

Summary

Spago Nanomedical AB faces substantial financial challenges, characterized by persistent losses, negative equity, and reliance on external financing. While revenue growth is a positive sign, the company must address its operational inefficiencies and improve its cash flow management to achieve financial stability.

Income Statement

Spago Nanomedical AB has shown modest revenue growth in recent years, but it remains a small fraction compared to its substantial operating expenses, resulting in negative gross and net profit margins. The company's EBIT and EBITDA margins are negative, indicating challenges in operational efficiency and profitability.

Balance Sheet

The company's balance sheet reveals high liabilities relative to equity, resulting in a negative equity position in the most recent year. The absence of debt is a positive aspect, but the negative stockholders' equity and declining asset base represent significant financial risks.

Cash Flow

Spago Nanomedical AB has consistently negative operating and free cash flows, reflecting cash burn from operations. The company relies on financing activities to support its cash position, indicating potential sustainability issues if external funding becomes constrained.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	1.52M	1.91M	1.20M	1.05M	660.00K	342.00K
Gross Profit	-11.91M	-12.36M	-23.28M	-15.60M	-16.78M	-416.00K
EBITDA	-31.21M	-33.40M	-42.22M	-38.73M	-38.69M	-18.59M
Net Income	-30.99M	-32.51M	-42.22M	-39.31M	-39.08M	-18.90M
Balance Sheet
Total Assets	23.64M	39.58M	52.98M	205.95M	191.62M	162.82M
Cash, Cash Equivalents and Short-Term Investments	18.52M	32.47M	45.22M	62.10M	52.46M	28.45M
Total Debt	0.00	0.00	0.00	0.00	0.00	0.00
Total Liabilities	5.06M	6.35M	11.67M	8.80M	6.81M	3.15M
Stockholders Equity	18.59M	33.23M	41.32M	197.16M	184.81M	159.67M
Cash Flow
Free Cash Flow	-29.76M	-34.90M	-45.06M	-42.02M	-40.20M	-25.15M
Operating Cash Flow	-29.76M	-34.67M	-44.91M	-38.19M	-35.57M	-18.77M
Investing Cash Flow	668.00K	-230.00K	-506.00K	-3.83M	-4.63M	-6.38M
Financing Cash Flow	-85.00K	22.15M	28.53M	51.66M	64.21M	41.45M

Spago Nanomedical AB Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.11
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:SPAGO, the sentiment is Negative. The current price of 0.11 is below the 20-day moving average (MA) of 0.11, below the 50-day MA of 0.14, and below the 200-day MA of 0.16, indicating a bearish trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 44.76 is Neutral, neither overbought nor oversold. The STOCH value of 83.06 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SE:SPAGO.

Spago Nanomedical AB Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
NXTCL	47 Neutral	kr84.66M	―	-52.45%	―	2.56%	52.76%
MODTX	42 Neutral	€47.80M	-2.16	-166.94%	―	―	-19.35%
SPAGO	38 Underperform	€74.10M	―	-106.95%	―	-48.15%	51.95%
NICA	38 Underperform	€114.42M	-2.27	-294.38%	―	186.74%	73.17%
BIOSGN	34 Underperform	€109.66M	―	-201.21%	―	―	49.09%